Ignite Creation Date:
2024-05-06 @ 3:15 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04570410
Status:
RECRUITING
Last Update Posted:
2022-12-09
First Post:
2020-09-16
Brief Title:
Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
Trials of Primary Excision Combined With Preoperative Neoadjuvant Therapy and Adjuvant Therapy Was Used as a First-line Comprehensive Therapy for Oligometastasis of Urothelial CarcinomaUC
Status:
RECRUITING
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
treatment of primary focal resection plus lymph node dissection combined with chemotherapy and anti-programmed cell death 1PD-1 for Oligometastasis of urothelial carcinoma
Detailed Description:
The study is designed to demonstrate that Whether the perioperative comprehensive treatment of primary focal resection plus lymph node dissection combined with chemotherapy and anti-PD-1 can prolong the overall survival of patients narrow the range of metastatic lesions and improve the quality of life of patients
Compared with patients with extensive metastasis 2-year tumor-specific survival and overall survival of patients with oligometastatic bladder cancer were significantly increased 533 vs 161519 vs 154Gemcitabine plus cisplatin GC regimen has been shown to bring clinical benefits in neoadjuvant therapy of metastatic UCurothelial carcinoma
PD-1 inhibitors have been widely used in urothelial carcinoma in recent years and positive data have been obtained in both advanced patients and neoadjuvant patients
If successful in this trial it will serve to provide a therapeutic alternative for this patient who have oligometastasis of urothelial carcinoma
Compared with patients with extensive metastasis 2-year tumor-specific survival and overall survival of patients with oligometastatic bladder cancer were significantly increased 533 vs 161519 vs 154Gemcitabine plus cisplatin GC regimen has been shown to bring clinical benefits in neoadjuvant therapy of metastatic UCurothelial carcinoma
PD-1 inhibitors have been widely used in urothelial carcinoma in recent years and positive data have been obtained in both advanced patients and neoadjuvant patients
If successful in this trial it will serve to provide a therapeutic alternative for this patient who have oligometastasis of urothelial carcinoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None